These and multiple other studies have yielded important prognostic information and has led cytogenetically normal AML with NPM1 or biallelic CEBPA mutations in the absence of FLT3-ITD to be placed in a favorable risk category4. The gene discussed is FLT3; the disease is acute myeloid leukemia.